BeiGene, Ltd. (BGNE) PT Raised to $295 at Morgan Stanley
Tweet
Share
E-mailGet Alerts BGNE Hot Sheet
Price: $184.71 --0%
Rating Summary:
17 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
17 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison raised the price target on BeiGene, Ltd. (NASDAQ: BGNE) to $295.00 (from $290.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Monopar Therapeutics (MNPR) PT Raised to $133 at BTIG
- Workman Co Ltd (7564:JP) (WKISF) PT Lowered to JPY8,100 at Nomura/Instinet
- Riskified Ltd. (RSKD) PT Raised to $5.50 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
